Introducing: The AmoyDx® HANDLE Melanoma NGS Panel
The AmoyDx® HANDLE Melanoma NGS Panel is a Next-Generation Sequencing-based assay for the qualitative detection of SNVs and InDels in nine key melanoma genes.
Analyzing DNA from FFPE tissue with the AmoyDx® HANDLE Melanoma NGS Panel not only allows the analysis of common biomarkers, such as BRAF, but also the detection of mutations in two critical hotspot areas of the TERT promoter. On top of that, the fast and flexible HANDLE technology allows library preparation in only 5 hours with only one reaction tube per sample.
For more information about the AmoyDx® HANDLE Melanoma NGS Panel click here.
This product is for research use only (RUO).
Further topics
News about the IVDR
The IVDR, in force since May 26, 2022, represents a turning point in the EU-wide harmonization of patient safety. At the same time, it places high demands on us as manufacturers and on you as a user of in vitro diagnostic medical devices to implement the new regulation. We would like to meet this challenge together with you for the benefit of your patients. It is important to us to certify our portfolio of diagnostic solutions in compliance with the IVDR in due time. Therefore, we would like to keep you informed about our progress with the implementation of the IVDR.
Exciting news
Today, we are proud to announce that ZytoVision, our sister company, received the IVDR certification!
